Jon Arnason, MD
Internal Medicine · New York, NYNPI 1376701136
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Regeneron accounts for 82.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $19,137 and has fallen 61.4% since, to $7,396 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $953.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$26K
- E.r. Squibb & Sons, L.L.C.$4K
- Bristol Myers Squibb$2K
- Johnson & Johnson$37
Across 165 payments — averaging $26,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$3.6M
- E.r. Squibb & Sons, L.L.C.$327K
- Regeneron$199K
- Beigene, Ltd.$133K
- Gilead$28K
- Jazz Pharmaceuticals Inc.$2K
What the payments were for
- Consulting fees$18,39658%
- Travel & lodging$12,70340%
- Food & beverage$3611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 25 | $25,851 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,690 |
| Bristol Myers Squibb | 6 | $1,882 |
| Johnson & Johnson | 1 | $37 |
How this compares
$31,460 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 20 | $302,285 |
| Acyclovir | 36 | $665 |
| Tamsulosin Hcl | 14 | $247 |
| Prednisone | 12 | $78 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.